DemeRx - Press & Media

Press Release

2 years ago

DemeRx NB Inc. Advances Study for Alcohol Use Disorder Treatment

Press Release

5 months ago

DemeRx Announces Successful Completion of Multiple Ascending Dose Clinical Trial of DMX-1001 for the Treatment of Alcohol Use Disorder (AUD)

Press Release

7 months ago

In Waves and War: Healing Trauma Through the Science of Neuroplasticity

Upcoming Events

7 months ago

Eudēmonia Talent Portal | Deborah Mash – Dec 14, 15, 16

Press Release

7 months ago

DemeRx Awarded $1.7 Million National Institutes of Health Grant

Upcoming Events

7 months ago

Ibogaine: Past Advances and Future Perspectives – Oct 23

News beats

11 months ago

DemeRx Welcomes E. Matthew “Whiz” Buckley to Advisory Board

Press Release

11 months ago

DemeRx Appoints Biopharma Industry Veteran Vic Pirotsky to Board of Directors

Press Release

12 months ago

DemeRx Joins Medical Psychedelics Working Group to Advance Next-Generation Addiction Treatments

News beats

1 year ago

Addressing the addiction and mental health crises in the United States

News beats

2 years ago

Ibogaine and Noribogaine: Mechanisms and Therapeutic Potential as Addiction Medicines

News beats

2 years ago

Exploring the Future of VR and Digital Therapeutics

News beats

2 years ago

The Unparalleled Power of Ibogaine in Addiction Recovery With Tom Feegel, CEO of Beond

News beats

2 years ago

Breaking the Cycle of Addiction with Ibogaine

News beats

2 years ago

Ibogaine Receives Serious Media Attention

News beats

2 years ago

Powerful Psychedelic Gains Renewed Attention as a Treatment for Opioid Addiction

News beats

2 years ago

Psychedelics Today Ep. 448: Deborah C. Mash, Ph.D. – Ibogaine, Noribogaine, and the Challenges of Federal Drug Policy

News beats

2 years ago

Opium Addiction Market expected to rise – BioCorRx Inc, Delpor Inc, DemeRx Inc, Alar Pharmaceuticals, expected to drive market

News beats

2 years ago

Advocates of using psychedelic drug ibogaine to treat addiction say its risks to the heart can be mitigated in a controlled study

News beats

2 years ago

Kentucky’s $42 million allocation for psychedelics research for opioid addiction

News beats

2 years ago

Rewiring an Addicted Brain | Deborah Mash – The Lindsey Elmore Show (podcast)

News beats

2 years ago

Are Psychedelics The Solution To The Opioid Crisis? – Dr. Mark Hyman

News beats

2 years ago

10 Psychedelics CEOs To Pay Attention To In 2022

News beats

2 years ago

Breaking the Cycle of Opioid Dependence with ibogaine

News beats

2 years ago

Goop podcast: The Future of Addiction Treatment

News beats

2 years ago

Ibogaine Therapies: Remodelling the Addicted Brain

News beats

2 years ago

Can a Shrub in Gabon Cure Addiction?

News beats

2 years ago

Dr. Deborah Mash on Why Ibogaine Treatment Aftercare is Key to Treating the Roots of Addiction

News beats

2 years ago

Investors & Media

DemeRx NB Inc. Advances Study for Alcohol Use Disorder Treatment

DemeRx Announces Successful Completion of Multiple Ascending Dose Clinical Trial of DMX-1001 for the Treatment of Alcohol Use Disorder (AUD)

In Waves and War: Healing Trauma Through the Science of Neuroplasticity

Eudēmonia Talent Portal | Deborah Mash – Dec 14, 15, 16

DemeRx Awarded $1.7 Million National Institutes of Health Grant

Ibogaine: Past Advances and Future Perspectives – Oct 23

DemeRx Welcomes E. Matthew “Whiz” Buckley to Advisory Board

DemeRx Appoints Biopharma Industry Veteran Vic Pirotsky to Board of Directors

DemeRx Joins Medical Psychedelics Working Group to Advance Next-Generation Addiction Treatments

Addressing the addiction and mental health crises in the United States

Ibogaine and Noribogaine: Mechanisms and Therapeutic Potential as Addiction Medicines

Exploring the Future of VR and Digital Therapeutics

The Unparalleled Power of Ibogaine in Addiction Recovery With Tom Feegel, CEO of Beond

Breaking the Cycle of Addiction with Ibogaine

Ibogaine Receives Serious Media Attention

Powerful Psychedelic Gains Renewed Attention as a Treatment for Opioid Addiction

Psychedelics Today Ep. 448: Deborah C. Mash, Ph.D. – Ibogaine, Noribogaine, and the Challenges of Federal Drug Policy

Opium Addiction Market expected to rise – BioCorRx Inc, Delpor Inc, DemeRx Inc, Alar Pharmaceuticals, expected to drive market

Advocates of using psychedelic drug ibogaine to treat addiction say its risks to the heart can be mitigated in a controlled study

Kentucky’s $42 million allocation for psychedelics research for opioid addiction

Rewiring an Addicted Brain | Deborah Mash – The Lindsey Elmore Show (podcast)

Are Psychedelics The Solution To The Opioid Crisis? – Dr. Mark Hyman

10 Psychedelics CEOs To Pay Attention To In 2022

Breaking the Cycle of Opioid Dependence with ibogaine

Goop podcast: The Future of Addiction Treatment

Ibogaine Therapies: Remodelling the Addicted Brain

Can a Shrub in Gabon Cure Addiction?

Dr. Deborah Mash on Why Ibogaine Treatment Aftercare is Key to Treating the Roots of Addiction

A Medicine that May Cure Drug Addiction: ibogaine